Q-omics provides the consensus-scored TNFRSF11A profile across patient tissues and cancer cell-line models. TNFRSF11A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TNFRSF11A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TNFRSF11A RNA expression shows 17,210 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, HNSC, and UVM as cancer lineages where TNFRSF11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF11A survival associations across molecular data types. TNFRSF11A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF11A RNA expression–survival associations across cancer types. High TNFRSF11A expression shows unfavorable associations in UVM, KICH, KIRC and ESCA, but favorable associations in COAD and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TNFRSF11A RNA expression.
This table summarizes TNFRSF11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF11A shows lower tumor expression in HNSC, COAD and THCA and higher tumor expression in KIRC, STAD and LUAD. The HNSC box plot shows higher TNFRSF11A RNA expression in normal versus tumor tissue (log2 FC = −1.087, t-test p < 0.001).
This table shows molecular features associated with TNFRSF11A in patient tissues and cancer cell lines. In patient samples, TNFRSF11A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
